0000012208-26-000010
SEC filingBio-Rad Laboratories, Inc. (BIO) reported FY 2025 net sales of $2.58B, with gross profit of $1.34B reflecting a gross margin of approximately 51.9%. Despite operating income of $47.2M impacted by $172.8M in impairment charges and $844.3M in SG&A expenses, the company achieved net income of $759.9M, driven primarily by $900.4M gains from changes in fair market value of equity securities and loan receivable, plus $235.6M tax benefit. Earnings per diluted share reached $28 on 27.3M weighted average shares. Balance sheet remains strong with $10.58B total assets, including $6.10B in other investments, $529.8M cash, and $7.45B stockholders' equity. Operating cash flow of $532.2M supported a net cash increase of $42.4M despite $189.7M investing outflow and $283.2M financing uses, primarily treasury stock purchases. No prior year figures disclosed in filing limits YoY analysis, but robust liquidity and investment gains position Bio-Rad for strategic growth in life sciences and clinical diagnostics.
Bio-Rad Laboratories, Inc. delivered FY 2025 net sales of $2.58B and gross profit of $1.34B. Operating income was $47.2M after $844.3M SG&A, $275.6M R&D, and $172.8M impairment charges. Exceptional $900.4M gains from fair market value changes of equity securities and loan receivable, combined with $6.6M foreign exchange gains and $90.3M other income, drove pre-tax income to $995.5M. A $235.6M tax benefit resulted in net income of $759.9M, or $28 per diluted share on 27.3M shares. Total assets stood at $10.58B with $7.45B equity. No prior period figures provided in the filing for direct YoY comparison.
Net sales totaled $2.58B for the fiscal year ended 2025-12-31. No segment breakdowns, geographic revenue mix, or specific growth drivers disclosed in the provided filing content. Cost of goods sold was $1.24B, yielding gross profit of $1.34B.
Gross margin was 51.9% ($1.34B gross profit / $2.58B revenue). Operating margin compressed to 1.8% ($47.2M / $2.58B revenue) due to $172.8M impairment of purchased intangibles, elevated $844.3M SG&A (32.7% of sales), and $275.6M R&D (10.7% of sales). Investment gains significantly boosted net profitability to 29.5% net margin. No prior year margins available for trend analysis.
Operating activities generated $532.2M, driven by $2.66B customer cash receipts offset by $2.06B supplier/employee payments. Investing activities used $189.7M, including $218.5M acquisitions and $157.6M capex, partially offset by $793.6M investment sales. Financing outflow of $283.2M primarily from $295.5M treasury stock purchases. Net cash increase was $42.4M, with ending cash at $529.8M. Balance sheet shows $2.91B current assets, $3.12B liabilities (debt $1.20B), and strong $7.45B equity with $8.18B retained earnings.
No management guidance, strategic priorities, or specific risk factors disclosed in the provided 10-K filing content.